Patent · US Active

Composition for the treatment of cystic fibrosis

US9504663B2 · kind B2 · utility

3Cited by

0References

13Claims

0Family size

Assignee

SciPharm S.à.r.l · LU

Inventors

Michael Freissmuth · Wien, AT
Christina Gloeckel · Wien, AT
Xaver Koenig · Weitensfeld im Gurktal, AT
Simon Keuerleber · Wien, AT

Key dates

Filing date	Feb 3, 2012
Grant date	Nov 29, 2016
Priority date	—
Expiry date	Feb 3, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a composition comprising at least one prostacyclin or prostacyclin analog or a pharmaceutically acceptable salt thereof and at least one phosphodiesterase (PDE) 4 inhibitor and optionally a further PDE inhibitor for use in preventing or treating cystic fibrosis by selectively increasing the cAMP levels in bronchoepithelial cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.